Mon-Fri 9:00-18:00 CET+39 095 7211344info@vitasanlabs.com

Family · Pharmaceutical analytical standards

Remdesivir

A prodrug of a nucleotide analogue that blocks the viral RNA polymerase, halting the copying of the virus genome. On 22 October 2020 it became the first medicine approved in the United States for COVID-19. This family brings together the active ingredient, metabolites, labelled standards and other impurities.

Did you know?It was born in 2009 as a candidate against hepatitis C and respiratory syncytial virus; it did not work, was studied against Ebola and Marburg, and only later found its way against the coronavirus.

RemdesivirGo to the active ingredient →
RemdesivirActive ingredientRemdesivirCat. No. P-R030-001CAS 1809249-37-3
Remdesivir-d4Isotopically labelledRemdesivir-d4Cat. No. P-R030-012CAS 2738376-82-2

Need a molecule you cannot find?

Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.